Gyre Therapeutics (GYRE) Other Operating Expenses (2014 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Other Operating Expenses of $17.9 million for Q1 2026, up 52.67% year-over-year from $11.7 million in Q1 2025, and up 895900.0% quarter-over-quarter from -$2000.0 in Q4 2025.
Gyre Therapeutics (GYRE) Other Operating Expenses (2014 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Other Operating Expenses for 11 consecutive years, with $17.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Operating Expenses rose 52.67% year-over-year to $17.9 million; the TTM figure through Mar 2026 stood at $17.9 million (up 53.5% YoY), while the FY2025 annual figure was -$4000.0, up 93.94% from the prior year.
- Other Operating Expenses advanced to $17.9 million in Q1 2026 per GYRE's latest filing, from -$2000.0 in the prior quarter.
- Across five years, Other Operating Expenses topped out at $57.2 million in Q2 2022 and bottomed at -$57.2 million in Q4 2022.
- Historically, Other Operating Expenses has averaged $3.3 million across 5 years, with a median of $500.0 in 2024.
- Annual changes were most pronounced in 2022 — Other Operating Expenses jumped 4925.9% — and 2025, when it plunged 200.0%.
- Gyre Therapeutics' Other Operating Expenses stood at -$57.2 million in 2022, then jumped by 96.2% to -$2.2 million in 2023, then soared by 100.09% to $2000.0 in 2024, then slumped by 200.0% to -$2000.0 in 2025, then jumped by 895900.0% to $17.9 million in 2026.
- Business Quant data shows GYRE's Other Operating Expenses at $17.9 million in Q1 2026, -$2000.0 in Q4 2025, and -$1000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.84 Mn |
| Mar 31, 2026 | 17.92 Mn |
| Dec 31, 2025 | -2,000.00 |
| Sep 30, 2025 | -1,000.00 |
| Jun 30, 2025 | -1,000.00 |
| Mar 31, 2025 | 11.74 Mn |
| Dec 31, 2024 | 2,000.00 |
| Jun 30, 2024 | -68,000.00 |
| Mar 31, 2024 | 13.52 Mn |
| Dec 31, 2023 | -2.17 Mn |
| Sep 30, 2023 | -526,000.00 |
| Mar 31, 2023 | 4.74 Mn |
| Dec 31, 2022 | -57.25 Mn |
| Jun 30, 2022 | 57.25 Mn |
| Mar 31, 2022 | 798,000.00 |
| Dec 31, 2021 | 68.74 Mn |
| Sep 30, 2021 | 2.31 Mn |
| Jun 30, 2021 | 1.14 Mn |
| Mar 31, 2021 | 1.48 Mn |
| Dec 31, 2020 | 46.11 Mn |